<DOC>
<DOCNO>EP-0633028</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Vaccine against lyme disease
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3800	A61K3800	C07K14005	C07K100	A61K3902	C12P2108	C12R101	C07K1900	G01N33569	A61K39395	C12P2108	C12N510	C12N1509	C12N1556	C07K1900	A61K3900	C07K14195	A61K3902	A61K3940	C12N120	C07K1400	C07K1400	C07K122	C12N1502	G01N33569	C07K1612	C12R119	C12N1531	C12N1531	C07H2104	C07K1441	A61K3940	G01N33577	C12R191	C12N520	A61K39395	C07K1600	C12N1509	C12P2102	G01N33577	C12P2102	C07K1441	C07H2100	C12N1556	C07K1612	C12N120	C07K1420	C07K14005	C12N510	C12N1563	C07K1600	C12N1502	C07K14195	C12N520	C12N1563	A61K3900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	C07K	C07K	A61K	C12P	C12R	C07K	G01N	A61K	C12P	C12N	C12N	C12N	C07K	A61K	C07K	A61K	A61K	C12N	C07K	C07K	C07K	C12N	G01N	C07K	C12R	C12N	C12N	C07H	C07K	A61K	G01N	C12R	C12N	A61K	C07K	C12N	C12P	G01N	C12P	C07K	C07H	C12N	C07K	C12N	C07K	C07K	C12N	C12N	C07K	C12N	C07K	C12N	C12N	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61K38	C07K14	C07K1	A61K39	C12P21	C12R1	C07K19	G01N33	A61K39	C12P21	C12N5	C12N15	C12N15	C07K19	A61K39	C07K14	A61K39	A61K39	C12N1	C07K14	C07K14	C07K1	C12N15	G01N33	C07K16	C12R1	C12N15	C12N15	C07H21	C07K14	A61K39	G01N33	C12R1	C12N5	A61K39	C07K16	C12N15	C12P21	G01N33	C12P21	C07K14	C07H21	C12N15	C07K16	C12N1	C07K14	C07K14	C12N5	C12N15	C07K16	C12N15	C07K14	C12N5	C12N15	A61K39	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to a passive vaccine against Lyme disease which contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) and/or the 34 kD antigen (OspB) of B. burgdorferi and prevents the development of arthritis, pancarditis and hepatitis in immunodeficient experimental animals which have been infected with viable pathogenic B. burgdorferi organisms. The invention furthermore relates to a process for obtaining the vaccine according to the invention, to the hybridoma cell lines ECACC 89091302, ECACC 90050405, ECACC 90050406 and ECACC 90050407 which secrete antibodies according to the invention and to the pathogenic B. burgdorferi strain ZS7 (DSM 5527). The invention likewise relates to an antigen from B. burgdorferi which reacts immunologically with an antibody according to the invention, to a process for obtaining antigens according to the invention, and to active vaccines against Lyme disease which contain an antigen according to the invention as essential ingredient. The invention finally relates to a method for isolating and recultivating pathogenic B. burgdorferi organisms from immunodeficient experimental animals.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
DEUTSCHES KREBSFORSCH
</APPLICANT-NAME>
<APPLICANT-NAME>
MAX PLANCK GESELLSCHAFT
</APPLICANT-NAME>
<APPLICANT-NAME>
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
EICHMANN KLAUS PROF DR
</INVENTOR-NAME>
<INVENTOR-NAME>
KRAMER MICHAEL DR
</INVENTOR-NAME>
<INVENTOR-NAME>
REINHARD WALLICH DR
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHAIBLE ULRICH E
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMON MARKUS M DR
</INVENTOR-NAME>
<INVENTOR-NAME>
EICHMANN, KLAUS, PROF.DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
KRAMER, MICHAEL, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
REINHARD, WALLICH, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHAIBLE, ULRICH E.
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMON, MARKUS, M., DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Claims for the following Contracting States :
AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE
Process for producing a vaccine against Lyme
disease,
wherein

experimental animals are immunized with the 31 kD
antigen (OspA) or/and with the 34 kD antigen (OspB)

of B. burgdorferi ZS7 (DSM 5527) and protective,
polyclonal or monoclonal antibodies against OspA

or/and OspB are isolated in the usual manner from
the immunized experimental animal.
Process as claimed in claim 1,
wherein

mice are used as experimental animals.
Claims for the following Contracting States : ES, GR
Process for producing a vaccine against Lyme
disease,
wherein

experimental animals are immunized with the 31 kD
antigen (OspA) or/and with the 34 kD antigen (OspB)

of B. burgdorferi and protective, polyclonal or
monoclonal antibodies against OspA or/and OspB are

isolated in the usual manner from the immunized
experimental animal.
Process as claimed in claim 1,
wherein

mice are used as experimental animals.
Process as claimed in claim 1 or 2,
wherein

the OspA antigen or/and the OspB antigen from B.
burgdorferi ZS7 (DSM 5527) is used.
</CLAIMS>
</TEXT>
</DOC>
